Market Pressure, Part I: Biotechs Feel the Chill
This article was originally published in Start Up
Dismal conditions in the public capital markets can't help but affect biotech start-ups too. Venture capitalists are reassessing operating and exit strategies, and contemplating new business models.
You may also be interested in...
Terrorism has lowered investors' tolerance for risk. Investors aren't willing to accept as they have in the past the traditional uncertainties of biopharmaceutical investing. Instead, they are looking for companies that understand how to manage all risk, starting with technology and extending into partnering potential, the regulatory arena, and the marketplace. Beyond these visible dangers lies a subtle one: the societal risk posed by the drug industry's aggressive pricing strategies.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.